Peptides for Longevity

Peptides have moved quickly from bodybuilding forums to longevity clinics and social media, often sold as injections promising repair, energy or youth. If you’re looking into peptides for longevity, Humanic Blue separates two very different things: tested prescription drugs and a much larger group of compounds with little human evidence.

A peptide is a short chain of amino acids, the building blocks of proteins, and some are well-tested medicines. In a large trial of adults with cardiovascular disease and overweight or obesity, but no diabetes, the peptide drug semaglutide reduced cardiovascular deaths, heart attacks or strokes compared with placebo. That finding does not establish an anti-aging effect in healthy people. But the peptides most marketed for longevity, such as BPC-157, TB-500, epitalon and MOTS-c, have sparse or absent human evidence for the uses clinics promote. At a July 2026 FDA advisory meeting, agency reviewers recommended against adding seven peptide-related substances to a pharmacy-compounding list; the committee recommended most anyway, but its votes were nonbinding. For living longer and better, no peptide marketed as a longevity therapy has been shown to extend human life.

Which peptide drugs have outcome trials?

Many medicines are peptides, including insulin and drugs that act like the hormone GLP-1, which helps regulate blood sugar and appetite. In SELECT, about 17,600 adults aged 45 or older with established cardiovascular disease and overweight or obesity, but no diabetes, received semaglutide or placebo. Over about 40 months, cardiovascular death, heart attack or stroke occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. That is a difference of 1.5 percentage points, or a 20% relative reduction—not 20 fewer events per 100 people. More participants stopped semaglutide because of adverse events. This was a trial in a defined clinical population, not proof that peptides as a class extend healthy people’s lives. Novo Nordisk, the drug’s maker, funded it. The FDA subsequently approved Wegovy for cardiovascular-risk reduction in adults with cardiovascular disease and overweight or obesity.

These drugs are prescribed for specific conditions, with dosing, monitoring and known risks. They show what peptide medicine looks like when it’s been tested.

What do we know about wellness peptides?

For peptides marketed through longevity clinics, the human evidence is sparse or absent for the advertised uses.

The peptides most associated with longevity clinics are different. At the FDA’s July 2026 Pharmacy Compounding Advisory Committee meeting, the agency reviewed seven for possible inclusion on the list of bulk ingredients used in pharmacy compounding—preparing a medicine for an individual patient: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax and epitalon.

The evidence FDA reviewers described. The agency’s meeting page and briefing packages show that staff recommended against including all seven substances. For BPC-157, FDA described small, short reports involving enemas or injections into joints, the bladder or a vein. Much of this evidence existed only as abstracts or retrospective reports, with limited safety detail. FDA found no adequate evidence for the proposed ulcerative-colitis use and no publicly available human administration studies for MOTS-c or clinical evidence supporting its nominated uses.

The identity problem. FDA’s reviews described uncertainty about how some nominated names map to a specific chemical substance, along with risks from immune reactions, impurities and uncertainty about the active ingredient’s chemical identity. That is a manufacturing and identity problem as well as an efficacy problem; a clinic’s label does not establish that the vial matches a research material.

The vote. FDA’s archived meeting records 8–6 votes, with one abstention, recommending BPC-157, KPV and TB-500, and a narrower favorable vote for MOTS-c. The committee also recommended epitalon and Semax and rejected emideltide. These were recommendations about whether specified bulk substances should go on the section 503A compounding list, named for the provision in US drug law governing this type of compounding—not findings that the peptides are FDA-approved, effective for longevity or safe for general use. FDA says advisory recommendations are nonbinding, and adding a substance requires the agency’s formal rulemaking.

What would connect evidence for a particular peptide to the use advertised by a longevity clinic?

Did the advisory vote make these peptides legal?

No. The vote was nonbinding and did not approve the substances or itself permit their compounding.

Several of the peptides had appeared in FDA’s Category 2, meaning the agency had identified significant safety concerns under its interim compounding policy. In April 2026, FDA removed BPC-157, epitalon and some others from that category because their nominations were withdrawn, while electing to take new, more specifically defined nominations to the advisory committee. Removal for that procedural reason did not resolve the safety concerns: FDA’s current safety-risk page still describes limited safety information, possible immune reactions, impurities and uncertainty about BPC-157’s chemical identity.

As of September 29, 2026, FDA’s compounding policy and rules page showed no final rule adding these substances to the 503A Bulks List. The advisory vote therefore did not approve the substances or itself make their compounding permissible. Products sold online as “research chemicals” are not approved human drugs, and that label is not a quality or safety credential.

What separates an advisory committee vote from an FDA decision about approval or compounding?